Vivo Capital related stories
All articles and analysis
Outpost Medicine forms senior leadership teamOutpost Medicine said July 18 that Nancy Martin, M.D., Pharm.D., has joined as a SVP, Chief Medical Officer, while Gordon McMurray, Ph.D., was named Chief Scientific Officer and Gayle Kennedy was appointed VP, Clinical Development. And Mike Ramsay was named VP, Manufacturing.
- Vivo Capital closes $100 mln healthcare VC fund
Vivo Capital closed the Vivo PANDA Fund, a new healthcare venture capital fund, at over $100 million. The firm intends to invest the new capital in early-state companies in sectors including pharmaceuticals, biotechnology, medical devices and diagnostics.
- New PE firm Sweetwater Capital Partners launches
Sweetwater Capital Partners, a new private equity firm, has launched. James Gamett, a former partner and head of secondaries at StepStone Group as well as a founder of Madison Creek Partners, will serve as SWCP's managing partner. Joining him are Brooks Lindberg as managing director; Joseph Siletto as managing director; Ron Heinz as principal; and Cameron Rondo as senior associate. The firm will focus mostly on the U.S.
- Life sciences-focused venBio raises $315 mln for second fund
San Francisco-based venBio Partners announced it has raised $315 million for its second life science fund, which is anchored by investments from strategic LPs Amgen, Merck and Baxalta. The amount exceeds the $250 million target it set in March 2015, according to a regulatory filing. The firm, which also has an office in New York, typically invests in clinical-stage life science companies with a therapeutic product.
- Life sciences-focused venBio raises $315 mln for second fund
San Francisco-based venBio Partners announced it has raised $315 million for its second life science fund, which is anchored by investments from strategic LPs Amgen, Merck and Baxalta. The amount exceeds the $250 million target it set in March 2015, according to a regulatory filing. The firm, which also has an office in New York, typically invests in clinical-stage life science companies with a therapeutic product.
- Longitude Capital leads $68 mln funding in Kala Pharmaceuticals
Longitude Capital led a $68 million Series C preferred stock financing in Kala Pharmaceuticals, Inc., which develops ophthalmic products. New investors in the funding included OrbiMed, Vivo Capital and CAM Capital. Existing investors in the funding included RA Capital Management, Wellington Management Company LLP, Polaris Partners, Lux Capital, CVF, LLC and others. Gregory Grunberg, managing director at Longitude Capital, and Chen Yu, managing partner at Vivo Capital, are joining Kala's board as new board members.
- Outpost Medicine raises $41 mln
Takeda Pharmaceutical Company Ltd and Frazier Healthcare Partners have formed Outpost Medicine, which just completed a $41 million financing led by Frazier Healthcare. Other investors include Adams Street Partners, Novo A/S, and Vivo Capital. Outpost Medicine is developing treatments for urologic and gynecologic diseases and disorders.
Taking a fresh look at medtechDavid Eichler, managing partner at Psilos, talks about opportunistic investing in a changing medical equipment market
- Crinetics scores $40 mln Series A
San Diego, California-based Crinetics Pharmaceuticals, which is focused on treating specialty endocrine disorders, has closed $40 million in Series A financing. Versant Ventures, 5AM Ventures and Vivo Capital led the round. In addition to the funding, Dr. Wendell Wierenga has been named chairman of Crinetics’ board of directors. Also, Crinetics has appointed Dr. Mason Freeman of 5AM Ventures, Dr. Steve Kaldor of Versant Ventures and Dr. Mahendra Shah of Vivo Capital to its board of directors.
- VC-backed IPO profiles from September 2015
Quick profiles of the three venture-backed IPOs that went out on U.S. exchanges in September: Regenxbio, Penumbra and Nabriva Therapeutics.